For the latest news and information on the coronavirus pandemic, visit the WHO and CDC websites.
The FDA is expected to approve Novavax, a new vaccine against COVID-19, although it is still in the revision phase.
Why it matters
Novavax will be the first protein-based vaccine for COVID-19 available in the United States, although the technology has been around for decades. Although this type of vaccine has some advantages in a pandemic, it also has unique challenges.
The FDA and CDC will have to decide how, or whether, the U.S. uses Novavax.
To solidify the vaccine plan for the expected winter increase in COVID-19, a committee of scientists and other experts advising the U.S. Food and Drug Administration should meet in late June to decide how the U.S. should modify its COVID-19. 19 vaccine.
The same commission earlier this month, a protein-based vaccine against COVID-19, for approval. If the FDA gives it the green light, it will be the fourth COVID-19 vaccine on the U.S. market and the first to use more traditional coronavirus protein-based vaccine technology.
It will also be another additional tool the country has in its fight against COVID-19, but another that is based on what is called the ancient strain of COVID-19. While ancestral-based vaccines continue to provide protection against serious illness and death, health regulators are debating whether older vaccine formulas should be the way forward.
More than two years after the pandemic, most Americans (about 67%) have been fully vaccinated against COVID-19, and many have added. Those who hesitate or oppose vaccination appear to continue with these attitudes, according to a survey by the Kaiser Family Foundation. The percentage of American adults who responded to the survey and said they would “definitely not” get the COVID-19 vaccine ranged from 15% in December 2020 to 17% in April 2022.
Novavax had a contract with the federal government through Operation Warp Speed, but experienced manufacturing problems that hampered potential approval for emergency use. In addition to examining more data on how Novavax behaves in relation to the omicron variant, the FDA will have to sign the company’s production before approving the vaccine.
However, some scientists hope that Novavax could one day be used as an additional dose in combination with other vaccines and that its primary batch could meet the need for a more traditional and potentially equally effective vaccine against COVID-19. It is also already available in other countries, including Canada and Australia, under the name Nuvaxovid.
“It’s good to have a vaccine like Novavax because it’s another option for those who may have contraindications to other vaccine platforms,” Ross Kedl, a professor of immunology and microbiology at the University of Colorado Anschutz Medical Campus, said in an email. “Some have allergic reactions or less often problems like blood clots.”
The Johnson & Johnson vaccine against COVID-19 is still approved in the United States, but the use of the samedue to a rare but serious risk of blood clots. This leaves Pfizer and Modern Vaccine as the two currently recommended options for most adults.
Authorizing Novavax also opens the door to use as a dose or part aapproach with other vaccines against COVID-19.
Here’s what you need to know.
What is Novavax? How is it different?
Novavax is a vaccine against COVID-19 that uses more traditional protein-based technology, unlike other vaccines currently available in the U.S.: Pfizer-BioNTech and Moderna use mRNA technology, and Johnson & Johnson is a viral-vector vaccine.
In the Novavax vaccine, the purified virus protein is mixed with what is called an adjuvant – additives that “be the immune response and tell it to take this target seriously,” Kedl said.
Dr. Glenn Wortmann, an infectious disease specialist at MedStar Health, said the general approach to most vaccines is to use a protein base.
“In particular, Novavax is very similar to the hepatitis B vaccine that most of us receive as children,” Wortmann said. Some vaccines for flu, shingles and other diseases use similar technology.
However, although it offers another option, the jury may not be questioning whether Novavax offers superior immunity to Pfizer and Modern vaccines.
“Immune-wise, in my opinion, it doesn’t in itself bring much that isn’t already well resolved by mRNA vaccines,” Kedl said.
However, it is easier to store and ship than mRNA vaccines, he said. This can be an advantage when vaccinating hard-to-reach communities where keeping picky vaccines in the refrigerator could be difficult. But Novavax has serious shortcomings when it comes to production, Kedl said, because it is not cheap for the company to produce and purify proteins.
“mRNA vaccines skip that step because they turn each individual into their own vaccine manufacturer,” he said. mRNA vaccines work by teaching our cells to produce a protein that will trigger an immune response.
For that reason, the mRNA of the vaccine is easier to adapt than Novavax when a new variant appears, Kedl said.
“The mRNA platform is much more flexible than what Novavax does,” he said. “Every time a new variant of the vaccine needs to be made, Novavax will have to do a lot of work in the lab to figure out what changes will still allow good protein to be made and purified in large quantities.”
How effective is Novavax?
Published study results revealed that Novavax was more than 90% effective against symptomatic COVID-19 and 100% effective against severe illness and death. But it is important that this study was conducted before omicron or delta variants were widely circulated. Both delta and omicron variants – including omicron subvariants such as BA.2, BA.2.12.1 and BA.4 – are more contagious and avoid some immunity from vaccines and previous infections.
Real-world data comparing the effectiveness of Novavax with other vaccines do not yet exist. According to the World Health Organization, “it is impossible to compare vaccines directly because of the different approaches used in designing appropriate studies.”
When will Novavax be available?
The FDA still has to approve the primary batch (first set of injections, not dose doses). Although it usually accepts the recommendation of its advisory board, the agency needs to review more information.
When it does, a panel of experts from the Centers for Disease Control and Prevention will vote on whether to recommend Novavax and for whom, and then the CDC director will sign the recommendation.
The FDA’s advisory board is scheduled to meet in public on June 28 to discuss future vaccines for the COVID-19 vaccine – including a likely fall or winter increase in COVID-19.
Once approved and recommended, it is unclear exactly how much Novavax will compare to Moderna and Pfizer vaccines, which are found in pharmacies, clinics and doctor’s offices across the country. The U.S. government originally planned to buy 110 million doses of the vaccine, The New York Times reports, but the U.S. has sufficient supplies of COVID-19 vaccines for primary doses and supplemental injections.
How will the US pay for Novavax?
Although vaccines against COVID-19 were free and available to all Americans, funding was recently stopped in Congress, and federal officials warned that we were running out of money for COVID-19 tests, vaccines, treatments, and related costs. Some services for Americanshave already expired.
However, it is likely that vaccines against COVID-19 will remain free, at least for some time. Money for testing on COVID-19 and protective equipment is being moved to cover the cost of vaccines and treatment for the fall, the New York Times writes.
Can Novavax be used as an enhancer?
The FDA is considering approving Novavax as the primary batch (first two doses). If the FDA gives it the green light, it could very easily become another option in the U.S. amplifier catalog. Last fall, the FDA signedto authorized COVID-19 booster drugs or heterologous booster dose.
When there are data on the use of a vaccine such as Novavax with mRNA vaccines, “There may be people who have received three or four mRNA vaccines and might be interested in trying another vaccine as part of a mixing and merging strategy,” Wortmann said.
“I think the real advantage of the Novavax vaccine is in a broader sense,” Kedl said. “Because it now has another vaccine platform to mix and match with other vaccines.”
The information contained in this article is for educational and informational purposes only and is not intended as health or medical advice. Always consult your doctor or other qualified healthcare professional regarding any questions you may have about your health condition or health goals.